|
|
|
|
|
Legal status
Patent lapsed (non-payment of fees)
| (51) | INT.CL. | C07K 16/28 | (2006.01) |
| (11) | Number of the document | 3097121 |
| (13) | Kind of document | T |
| (96) | European patent application number | 15703384.6 |
| Date of filing the European patent application | 2015-01-23 | |
| (97) | Date of publication of the European application | 2016-11-30 |
| (45) | Date of publication and mention of the grant of the patent | 2018-12-19 |
| (46) | Date of publication of the claims translation | 2019-05-10 |
| (86) | Number | PCT/US2015/012754 |
| Date | 2015-01-23 |
| (87) | Number | WO 2015/112900 |
| Date | 2015-07-30 |
| (30) | Number | Date | Country code |
| 201461931512 P | 2014-01-24 | US | |
| 201462059676 P | 2014-10-03 | US | |
| 201462094834 P | 2014-12-19 | US |
| (72) |
FREEMAN, Gordon, James, US
SHARPE, Arlene, Helen, US
BLATTLER, Walter, A., US
MATARAZA, Jennifer, Marie, US
SABATOS-PEYTON, Catherine, Anne, US
CHANG, Hwai, Wen, US
FREY, Gerhard, Johann, US
|
| (73) |
Novartis AG,
Lichtstrasse 35, 4056 Basel,
CH
President and Fellows of Harvard College, 17 Quincy Street, Cambridge, MA 02138, US Dana-Farber Cancer Institute, Inc., 450 Brookline Avenue, Boston, MA 02115-5450, US |
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | Antikūno molekulės prieš PD-1 ir jų panaudojimas |
| ANTIBODY MOLECULES TO PD-1 AND USES THEREOF |
| Payment date | Validity (years) | Amount | |
| 2023-12-22 | 10 | 231.00 EUR |
| Patent lapsed (non-payment of fees) | ||
| Invalidation date | 2025-01-23 |